MBP8298 for the treatment of secondary progressive multiple

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
beyondms
Family Member
Posts: 63
Joined: Sat Nov 11, 2006 3:00 pm

MBP8298 for the treatment of secondary progressive multiple

Post by beyondms »

Today, I was offered the opportunity to enroll in the BioMS study looking at the effects of MBP8298 for the treatment of secondary progressive multiple sclerosis. Given that I have slowly but surely progressed in the last few years, I see little options. Let me know what you think.

thanks,

beyondms
User avatar
dignan
Family Elder
Posts: 1612
Joined: Wed Aug 11, 2004 2:00 pm

Post by dignan »

I like the sounds of it because it's an injection every six months, and so far, they don't seem to have experienced any scary side-effects. Have you already been tested to see if you have the right haplotype?
User avatar
mjs
Family Member
Posts: 42
Joined: Wed Jan 17, 2007 3:00 pm

Post by mjs »

Googling this drug only brings up good news. The mechanism of this drug also makes it more appealing in some ways (ie, not a general immunosuppressant). Good luck making your decision!
User avatar
beyondms
Family Member
Posts: 63
Joined: Sat Nov 11, 2006 3:00 pm

Post by beyondms »

dignan wrote:I like the sounds of it because it's an injection every six months, and so far, they don't seem to have experienced any scary side-effects. Have you already been tested to see if you have the right haplotype?
I have taken the blood test and I will find out soon if I am eligible for this drug. There are few options for SPMS but this one seems promising for a subgroup of patients. At the hospital, the nurse told me that two patients got worse, two had an improvement on their EDSS score by 1. The problem is that the nurse does not know who is on the placebo and who isn't. That five year study looks incredible but we need to complete this phase III study before passing judgment on the drug's efficacy for SPMS. Also note that BioMS is enrolling patients with RRMS for a new study. Stay tuned.

beyondMS
Post Reply

Return to “Drug Pipeline”